Acute leukemia

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

Thursday, October 21, 2021 - 12:00pm

The Phase 2 portion of the study will evaluate the efficacy of the combination in patients with previously untreated AML who are not candidates for intensive induction therapy.

Key Points: 
  • The Phase 2 portion of the study will evaluate the efficacy of the combination in patients with previously untreated AML who are not candidates for intensive induction therapy.
  • We are looking forward to evaluating the addition of evorpacept to venetoclax and azacitidine.
  • Through blockade of the CD47 myeloid checkpoint, evorpacept in combination with venetoclax and azacitidine may potentially transform treatment options for patients with AML.
  • ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignances, including acute myeloid leukemia and myelodysplastic syndromes.

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

Wednesday, October 20, 2021 - 7:21pm

The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.

Key Points: 
  • The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.
  • In the first-in-human EVICTION Phase I/IIa clinical trial, ICT01 demonstrated selective activation of V9V2 T cells, causing them to rapidly migrate out of the circulation and into tumor tissue.
  • Furthermore, ICT01-activated V9V2 T cells secrete IFN and TNFa that expands the anti-tumor immune response by recruiting CD3 and CD8 T cells into tumors.
  • BTN3A is essential for the activation of the anti-tumor immune response of V9V2 T cells.

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Monday, October 18, 2021 - 12:30pm

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
  • Completing patient enrollment in IMerge Phase 3 brings us one step closer to delivering imetelstat as a potential treatment alternative for patients with lower risk MDS who are relapsed or refractory to ESAs.
  • IMerge Phase 3 is a double-blind, randomized, placebo-controlled Phase 3 clinical trial with registrational intent.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

Friday, October 15, 2021 - 12:00pm

Hansoh Pharma is supported by over 12,000 dedicated employees in China and the United States.

Key Points: 
  • Hansoh Pharma is supported by over 12,000 dedicated employees in China and the United States.
  • Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.
  • Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL

Wednesday, October 13, 2021 - 12:00pm

In all cases, Smart-101 ProTcells will be cultured from the same donor from whom the patient has received the initial CD34+ HSCT.

Key Points: 
  • In all cases, Smart-101 ProTcells will be cultured from the same donor from whom the patient has received the initial CD34+ HSCT.
  • This trial will rely upon a prospectively generated control database of AML/ALL patients who undergo routine HSCTs at MSK.
  • Such proof can then pave the way for a more expedited clinical development of genetic engineered ProTcell in the future.
  • ProTcell is currently being studies in two clinical trials in Europe, with two in the U.S. expected to start in Q4 2021.

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China

Tuesday, October 12, 2021 - 12:00pm

Hansoh will have exclusive commercial rights to these therapeutics in Greater China and OliX will have rights in the rest of the world.

Key Points: 
  • Hansoh will have exclusive commercial rights to these therapeutics in Greater China and OliX will have rights in the rest of the world.
  • OliX will receive an initial upfront payment of $6.5 million with up to $450 million plus royalties based on key milestones.
  • OliX Pharmaceuticals innovative GalNAc-asiRNA platform allows us to consider unique gene silencing technology in addressing a broad range of unmet medical needs here in Greater China.
  • Compared to existing siRNA therapeutics, OliX Pharmaceuticals asiRNA shows comparable gene silencing and significantly reduced siRNA-mediated side effects such as off-target gene silencing and immune stimulation.

ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021

Friday, October 1, 2021 - 1:00pm

It is exciting to have the opportunity to present additional clinical data on ICT01 monotherapy and in combination with pembrolizumab from Part 1 of the ongoing EVICTION trial at SITC 2021.

Key Points: 
  • It is exciting to have the opportunity to present additional clinical data on ICT01 monotherapy and in combination with pembrolizumab from Part 1 of the ongoing EVICTION trial at SITC 2021.
  • BTN3A is essential for the activation of the anti-tumor immune response of 92 T cells.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
  • In addition, preclinical experiments with ImChecks antagonist antibodies have shown their potential as treatments for a wide range of autoimmune diseases.